Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Primary Biliary Cirrhosis (PBC) Clinical Research Samples
Discovery Life Sciences provides the highest quality Primary Biliary Cirrhosis (PBC) Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Primary Biliary Cirrhosis (PBC) Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 16 of 16 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Sample Detail 1 | Test 2 | Test Data 2 | Sample Detail 2 | Test 3 | Test Data 3 | Sample Detail 3 | Product Details | Price | Buy | Additional Information 1 | Additional Data 1 | Additional Detail 1 | Additional Information 2 | Additional Data 2 | Additional Detail 2 | Additional Information 3 | Additional Data 3 | Additional Detail 3 | Additional Information 4 | Additional Data 4 | Additional Detail 4 | Additional Information 5 | Additional Data 5 | Additional Information 6 | Additional Data 6 | Additional Information 7 | Additional Data 7 | Additional Detail 7 | ICD10 codes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DLS16-13638-K2 | Primary Biliary Cirrhosis (PBC) | Canada | K2 EDTA Plasma | 1.00 | 1.00 | $150.00 | 50 Y | F | White | <-70C | 20-Feb-17 | Clinical Diagnosis | Primary Biliary Cirrhosis | Ultrasound | Cholelithiasis | 18-Jan-14 | N/A | N/A | N/A | $150.00 | Initial Date of Disease Diagnosis | 25-Mar-2015 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | No | Comorbidities | CREST Syndrome | Current Prescription Medications | Ursodiol; Ibuprofen | ||||||||||||
| DLS16-87712-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $150.00 | 56 Y | M | Black | <-70C | 28-Sep-17 | Clinical Diagnosis | Primary Biliary Cirrhosis | CT AbdoMen | Cirrhosis and portal hypertension. Upper abdoMinal ascites. | 29-Jul-17 | $150.00 | Initial Date of Disease Diagnosis | Mar-15 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis? | Yes | CT AbdoMen 29-Jul-2017 | Comorbidities | Awaitng For organ transplant status, Esophageal varice, AdjustMent disorder | Current Prescription medications | CiproFloxacin HCL, Docusate sodiuM, Ferrous sulFate, FuroseMide, OMeprazole, Propanolol, Spironolactone | All Known Test Results Performed in Previous Six months | ALT: 35 U/L, AST: 41 U/L Bilirubin (direct): 1.2 Mg/dL, Bilirubin (total): 2.6 Mg/dL 7-Jul-2017 | ||||||||||||
| DLS16-82848-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 3.00 | $150.00 | 45 Y | F | White | <-70C | 03-Jul-17 | Clinical Diagnosis | Primary Biliary Cirrhosis | Ultrasound | Unremarkable | 27-May-17 | $150.00 | Initial Date of Disease Diagnosis | 5-Jun-2017 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | No | Comorbidities | Psoriatic arthritis, Status post-cholecystectomy and gastric bypass, ADHD | Current Prescription Medications | Ursodiol, Vyvanse, Adderall, Cymbalta, Restoril | All Known Test Results Performed in Previous Six Months | ALT: 100 U/L; AST: 106 U/L; GGT: 250 U/L; Bilirubin (direct): 0.12 mg/dL; Bilirubin (total): 0.2 mg/dL 26-May-2017; | |||||||||||||
| DLS16-13609-K2 | Primary Biliary Cirrhosis (PBC) | Canada | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 56 Y | F | White | <-70C | 16-Mar-18 | Clinical Diagnosis | Primary Biliary Cirrhosis | Ultrasound | Normal Liver | 7-Jul-17 | $150.00 | Initial Date of Disease Diagnosis | 12-May-2017 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | No | Comorbidities | None | Current Prescription Medications | Ursodial | All Known Test Results Performed in Previous Six months | ALT: 28 U/L | AST: 23 U/L | GGT: 72 U/L | Bilirubin (direct): 4 umol/L | Bilirubin (total): 12 umol/L 2-Feb-2018 | |||||||||||||
| KH18-16880 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $75.00 | 66 Y | M | White | <-70C | 13-Apr-18 | Abbott Architect | 20 U/L : ALT | Abbott Architect | 17 U/L | AST | $75.00 | BMI | 27.24 | Height | Weight | 177.8 | 86.1 | K74.3 | ||||||||||||||||||||||
| DLS17-026143-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 3.00 | $150.00 | 45 Y | F | Black | <-70C | 30-Mar-18 | Clinical Diagnosis | Primary Biliary Cirrhosis | $150.00 | Initial Date of Disease Diagnosis | 13-Mar-18 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | No | Comorbidities | GERD, Rectal bleeding, Pre-diabetes, Hypertension, Tobacco dependence | Current Prescription Medications | Amitriptyline, Amlodipine, Clonazepam, Gabapentin, Naproxen, Omeprazole, Prednisone, Varenicline, Loratadine | All Known Test Results Performed in Previous Six months | ALT: 32 U/L | AST: 28 U/L | GGT: 75 U/L | Bilirubin (total): 0.4 mg/dL | 13-Mar-2018 | Cholesterol: 198 mg/dL | Triglycerides: 126 mg/dL | HDL: 65 mg/dL | LDL: 108 mg/dL | 12-Feb-2018 | ||||||||||||||||
| DLS16-87714-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 3.00 | $150.00 | 59 Y | F | White | <-70C | 12-Dec-17 | Clinical Diagnosis | Primary Biliary Cirrhosis | $150.00 | Initial Date of Disease Diagnosis | 22-Jun-05 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | Yes | CT Liver | 07-Oct-14 | Comorbidities | Primary cholangitis, Asthma, Hepatic encephalopathy | Current Prescription Medications | Tylenol, Vitamin D, Furosemide, Hydroxyzine, Lactulose, Ursodiol, Tramadol, Omeprazole, Rifaximin | All Known Test Results Performed in Previous Six months | ALT: 20 U/L | AST: 22 U/L | Bilirubin (direct): 0.4 mg/dL | Bilirubin (total): 2.1 mg/dL | 12-Dec-2017 | |||||||||||||||
| DLS16-87716-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 4.00 | $150.00 | 56 Y | F | White | <-70C | 23-Feb-18 | Clinical Diagnosis | Primary Biliary Cirrhosis | $150.00 | Initial Date of Disease Diagnosis | 15-Feb-18 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | No | Comorbidities | Abnormal liver enzymes, Anemia, Fibromyalgia, Gastric antral vascular ectasia, Hypothyroidism, Vitamin D deficiency | Current Prescription Medications | Ferrous sulfate, Levothyroxine | All Known Test Results Performed in Previous Six months | None | ||||||||||||||||
| DLS17-038147-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 5.00 | $150.00 | 49 Y | F | White | <-70C | 05-Feb-18 | Clinical Diagnosis | Primary Biliary Cirrhosis | Ultrasound | No evidence of fatty liver. Gallstones present. | Jun-14 | $150.00 | Initial Date of Disease Diagnosis | Jun-2014 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | No | Comorbidities | None | Current Prescription Medications | Vyvanse, Zoloft, Wellbutrin XL, Ursodiol, Allegra | All Known Test Results Performed in Previous Six months | None | |||||||||||||
| DLS17-038143-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 74 Y | F | White | <-70C | 03-May-18 | Clinical Diagnosis | Primary Biliary Cirrhosis | CT | Cirrhotic hepatic morphology. Mild splenomegaly raised the question of portal hypertension | 10-Sep-10 | MRI | Cirrhotic appearance of liver | 1-Mar-10 | $150.00 | Initial Date of Disease Diagnosis | 2009 | Ever Developed Jaundice | No | Liver Biopsy | No | Cirrhosis | Yes | 1-Mar-2010 | MRI of abdomen | Comorbidities | Reflux, Thyroid disease, Hypertension, High cholesterol, Renal insufficiency. | Current Prescription Medications | Ursodiol, Synthroid, Lisinopril, Dicyclomine HCL, Promethazine HCL, Propranolol HCL, Bethanechol chloride | All Known Test Results Performed in Previous Six months | ALT: 141 U/L | AST: 271 U/L | Bilirubin (total): 0.4 mg/dL | 25-Apr-18 | ||||||||
| DLS16-13617-K2 | Primary Biliary Cirrhosis (PBC) | Canada | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 38 Y | M | White | <-70C | 25-Oct-18 | Clinical Diagnosis | Primary Biliary Cirrhosis | Ultrasound | Fatty infiltration. Liver is coarse and homogeneous | 6-Jun-18 | MRI | Diffuse abnormality of intrahepatic portal veins | 23-Oct-16 | $150.00 | Initial Date of Disease Diagnosis | 14-Aug-2017 (Diagnosed by liver biopsy) | Ever Developed Jaundice | fibrosis, mild non-specific inflammation, mild bile ductular reaction | 28-Sep-16 | Liver Biopsy | No | Cirrhosis? | No | Comorbidities | None | Current Prescription medications | Ursodiol | All Known Test Results Performed in Previous Six months | ALT: 119 U/L | AST: 85 U/L | GGT: 196 U/L | Bilirubin (direct): 6 umol/L | Bilirubin (total): 12 umol/L | 23-Oct-2018 | |||||||||
| KH19-087513 | Primary Biliary Cirrhosis (PBC) | USA | Serum | 1.75 | 1.00 | $75.00 | 57 Y | F | White | <-70C | 05-Jun-19 | Abbott Architect | 21 U/L ALT | Abbott Architect | 31 U/L | AST | $75.00 | Abbott Architect | 1.4 mg/dL | Bilirubin | BMI | 17.85 | Height | Weight | 157cm | 44kg | K74.3 | |||||||||||||||||||
| DLS17-038141-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 7.00 | $150.00 | 54 Y | F | White | <-70C | 09-Jan-19 | Clinical Diagnosis | PBC | Ultrasound | Fatty infiltration of liver | 8-Sep-16 | MRI | Liver mildly enlarged measuring 21 cm in length, Moderate diffuse hepatic steatosis | 23-May-18 | $150.00 | Initial Date of Disease Diagnosis | 10-Feb-14 | Ever Developed Jaundice | No | Liver Biopsy | Yes | Diagnosis of primary biliary cirrhosis | 10-Feb-14 | Cirrhosis | No | Comorbidities | Hyperlipidemia, Hypertension | Current Prescription Medications | Metoprolol succinate, Hydrochlorothiazide, Losartan potassium, Ursodiol | |||||||||||
| DLS17-038149-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 61 Y | F | White | <-70C | 18-Sep-18 | Clinical Diagnosis | PBC | Ultrasound | Slightly enlarged liver. No focal hepatitic lesions. No intrahepatic biliary duct dilatation. | 15-Apr-16 | $150.00 | Initial Date of Disease Diagnosis | 15-Feb-2007 | Ever Developed Jaundice | No | Liver Biopsy | Yes | Primary Biliary Cirrhosis | 15-Feb-07 | Cirrhosis | No | Comorbidities | Hyperlipidemia, GERD | Current Prescription Medications | Ursodiol | ||||||||||||||
| DLS17-038156-K2 | Primary Biliary Cirrhosis (PBC) | USA | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 72 Y | F | White | <-70C | 12-Jun-19 | Clinical Diagnosis | PBC | X-ray | Ultrasound | Nodular contour consistent with cirrhosis | Cirrhotic hepatic morphology without focal lesion | 5-July-2016 | 9-Aug-2018 | CT | No biliary ductal dilation. Similar mild atrophy of right hepatic lobe | 28-Nov-17 | $150.00 | Initial Date of Disease Diagnosis | 27-Aug-02 | Ever Developed Jaundice | No | Liver Biopsy | Yes | Chronic hepatitis compatible with PBC Stage 1 Fibrosis | 27-Aug-02 | Cirrhosis | Yes | CT scan | Nov-15 | Comorbidities | Hypertension, Thyroid disease, Atrial fibrillation | Current Prescription Medications | Atorvastatin, Digoxin, Montelukast, Spironolactone, Levoxyl, Letrozole, Ursodiol, Fosamax, Metoprolol succinate | ||||||||||
| KH19-093570 | Primary Biliary Cirrhosis (PBC) | USA | Serum | 1.00 | 1.00 | $75.00 | 75 Y | F | White | <-70C | 17-Jul-19 | Abbott Architect | 72 U/L | ALT | Abbott Architect | 164 U/L | AST | Abbott Architect | 0.4 | Bilirubin | $75.00 | BMI | 25.78 | Height | Weight | 160cm | 66kg | K74.3 |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.